Home › Research › Biomarkers
A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer
Ramanathan Rajagopalan, Sujatha Hariharan, N.R. Akshaya, R. Senthamarai. Global Journal of Medical Pharmaceutical and Biomedical Update, 2025-04-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The research focuses on the use of biomarkers to diagnose Alzheimer’s disease (AD) in living individuals. Biomarkers for AD are grouped into Aβ deposition, pathologic tau, and neurodegeneration. Other potential candidates for AD, which include Neurofilament light (NEFL) protein, glial fibrillary acidic protein (GFAP), and growth differentiation factor 15 (GDF15), have been found in recent studies in addition to the Aβ and tau proteins. This review primarily addresses the methods used in the study, which was published in the journal Nature Aging, to measure biomarkers using fludeoxyglucose positron emission tomography, single molecule array, cerebospinal fluid sampling and blood proteomics, and dementia investigation to date. Inferred from the analysis, plasma proteins, NEFL, GFAP, and GDF15 were shown to be highly rated in protein significance ranking and to be most consistently linked with incident dementia and AD. An individual with greater GFAP levels is 2.32 times likely to acquire dementia. Early diagnosis is crucial for those with dementia, as it ensures that they receive the help and support they need. Furthermore, new drugs, such as donanemab and lecanemab, may be able to delay the progression of AD.
What this study adds
Evidence grade: Low
This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with greater GFAP levels is 2.32 times likely to acquire dementia. It also notes that drugs such as donanemab and lecanemab may delay progression, but the review itself presents no new treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rajagopalan, R., Hariharan, S., Akshaya, N., & Senthamarai, R. (2025). A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer. Global Journal of Medical Pharmaceutical and Biomedical Update. https://doi.org/10.25259/gjmpbu_38_2024
Vancouver
Rajagopalan R, Hariharan S, Akshaya N, Senthamarai R. A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer. Global Journal of Medical Pharmaceutical and Biomedical Update. 2025. doi:10.25259/gjmpbu_38_2024.
BibTeX
@article{rajagopalan2025-5adb338a,
author = {Rajagopalan, Ramanathan and Hariharan, Sujatha and Akshaya, N.R. and Senthamarai, R.},
title = {{A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer}},
journal = {Global Journal of Medical Pharmaceutical and Biomedical Update},
year = {2025},
doi = {10.25259/gjmpbu_38_2024},
url = {https://doi.org/10.25259/gjmpbu_38_2024}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This review primarily addresses the methods used in the study, which was published in the journal Nature Aging, to measure biomarkers using fludeoxyglucose positron emission tomography, single molecule array, cerebospinal fluid sampling and blood proteomics, and dementia investigation to date.
- Inferred from the analysis, plasma proteins, NEFL, GFAP, and GDF15 were shown to be highly rated in protein significance ranking and to be most consistently linked with incident dementia and AD.
- An individual with greater GFAP levels is 2.32 times likely to acquire dementia.
- Early diagnosis is crucial for those with dementia, as it ensures that they receive the help and support they need.
- Furthermore, new drugs, such as donanemab and lecanemab, may be able to delay the progression of AD.
Why it matters
This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with greater GFAP levels is 2.32 times likely to acquire dementia. It also notes that drugs such as donanemab and lecanemab may delay progression, but the review itself presents no new treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 26 of the 97 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Global Journal of Medical Pharmaceutical and Biomedical Update) |
| Journal's citation record | 0 / 4 | Global Journal of Medical Pharmaceutical and Biomedical Update: journal h-index 8 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author R. Senthamarai: h-index 7 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 97 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Related studies in Biomarkers from nearby years
Also in Biomarkers
136 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.